Cite
HARVARD Citation
Hirbe, A. et al. (n.d.). 1677PDA phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy. Annals of oncology. p. . [Online].